Francisco RuÃ-z-Cabello

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3471483/publications.pdf

Version: 2024-02-01

185	8,825	38660	53109
papers	citations	50 h-index	85 g-index

191	191	191	8243
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Trends in Immunology, 1997, 18, 89-95.	7.5	708
2	Natural history of HLA expression during tumour development. Trends in Immunology, 1993, 14, 491-499.	7.5	432
3	Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. Gastroenterology, 2011, 141, 338-347.	0.6	412
4	The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunology, Immunotherapy, 2004, 53, 904-10.	2.0	239
5	Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2?-deoxycytidine treatment. International Journal of Cancer, 2001, 94, 243-251.	2.3	225
6	Analysis of HLA-E expression in human tumors. Immunogenetics, 2003, 54, 767-775.	1.2	143
7	Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: Î²2 -microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens, 2003, 61, 211-219.	1.0	134
8	Mutations of the Î²<sub>2â€microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens, 1998, 52, 520-529.	1.0	132
9	Immune escape of cancer cells with beta2â€microglobulin loss over the course of metastatic melanoma. International Journal of Cancer, 2014, 134, 102-113.	2.3	129
10	MHC Class I Antigens and Immune Surveillance in Transformed Cells. International Review of Cytology, 2007, 256, 139-189.	6.2	128
11	HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. British Journal of Cancer, 1989, 59, 221-226.	2.9	122
12	Hla Class I Antigens in Human Tumors. Advances in Cancer Research, 1995, 67, 155-195.	1.9	121
13	Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics, 2008, 60, 439-447.	1.2	119
14	Role of Altered Expression of HLA Class I Molecules in Cancer Progression. Advances in Experimental Medicine and Biology, 2007, 601, 123-131.	0.8	117
15	Coordinated downregulation of the antigen presentation machinery and HLA class I/Î²2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. International Journal of Cancer, 2005, 113, 605-610.	2.3	116
16	Rejection versus escape: the tumor MHC dilemma. Cancer Immunology, Immunotherapy, 2017, 66, 259-271.	2.0	115
17	Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens, 2000, 55, 401-411.	1.0	113
18	Implication of the Î²2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunology, Immunotherapy, 2012, 61, 1359-1371.	2.0	105

#	Article	IF	Citations
19	Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. , 1999, 83, 91-97.		104
20	The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses. Current Opinion in Immunology, 2018, 51, 123-132.	2.4	99
21	Analysis of HLA expression in human tumor tissues. Cancer Immunology, Immunotherapy, 2003, 52, 1-9.	2.0	98
22	Presence of hpv 16 sequences in laryngeal carcinomas. International Journal of Cancer, 1990, 46, 8-11.	2.3	97
23	Secretion by Trypanosoma cruzi of a peptidyl-prolyl cis-trans isomerase involved in cell infection.. EMBO Journal, 1995, 14, 2483-2490.	3.5	95
24	Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget, 2015, 6, 19204-19216.	0.8	93
25	Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica, 2004, 89, 58-69.	1.7	90
26	Complete loss of HLA class I antigen expression on melanoma cells: A result of successive mutational events. International Journal of Cancer, 2003, 103, 759-767.	2.3	88
27	Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. International Journal of Cancer, 1989, 43, 436-442.	2.3	86
28	Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens, 1996, 47, 372-381.	1.0	85
29	High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens, 1998, 52, 114-123.	1.0	84
30	Chapter 7 IFN Inducibility of Major Histocompatibility Antigens in Tumors. Advances in Cancer Research, 2008, 101, 249-276.	1.9	84
31	High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Human Immunology, 2007, 68, 698-704.	1.2	83
32	HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity. PLoS ONE, 2013, 8, e68111.	1.1	81
33	Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. International Journal of Cancer, 2001, 91, 109-119.	2.3	78
34	HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunology, Immunotherapy, 2007, 56, 709-717.	2.0	78
35	The absence of HLA class I expression in nonâ€small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration. International Journal of Cancer, 2017, 140, 888-899.	2.3	75
36	Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer, 2007, 7, 34.	1.1	74

#	Article	IF	Citations
37	Monoclonal TCR-VÎ²13.1+/CD4+/NKa+/CD8â^'/+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. Blood, 2007, 109, 4890-4898.	0.6	72
38	Analysis of IL-10, IL-4 and TNF-Î± polymorphisms in drug-induced liver injury (DILI) and its outcome. Journal of Hepatology, 2008, 49, 107-114.	1.8	72
39	Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clinical Pharmacology and Therapeutics, 1984, 36, 691-695.	2.3	69
40	HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape. Oncotarget, 2018, 9, 4120-4133.	0.8	66
41	Expression of HLA G in human tumors is not a frequent event. , 1999, 81, 512-518.		65
42	HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx. Clinical and Experimental Metastasis, 1990, 8, 319-328.	1.7	62
43	Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunology, Immunotherapy, 1998, 47, 113-120.	2.0	62
44	Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunology, Immunotherapy, 2005, 54, 858-866.	2.0	62
45	The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture. Vaccines, 2017, 5, 7.	2.1	62
46	Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Research, 1991, 51, 4948-54.	0.4	61
47	Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer, 2008, 8, 382.	1.1	59
48	Lack of MHC class I antigens and tumour aggressiveness of the squamous cell carcinoma of the larynx. British Journal of Cancer, 1990, 62, 1047-1051.	2.9	58
49	HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy. Cellular and Molecular Immunology, 2021, 18, 556-565.	4.8	55
50	Expanded cells in monoclonal TCR-Î±Î²+/CD4+/NKa+/CD8â^'/+dim T-LGL lymphocytosis recognize hCMV antigens. Blood, 2008, 112, 4609-4616.	0.6	54
51	HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunology, Immunotherapy, 2009, 58, 1507-1515.	2.0	53
52	Biological Implications of HLA-DR Expression in Tumours. Scandinavian Journal of Immunology, 1995, 41, 398-406.	1.3	52
53	Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Seminars in Cancer Biology, 1991, 2, 47-54.	4.3	51
54	MHC antigens on human tumors. Immunology Letters, 1991, 29, 181-189.	1.1	50

#	Article	IF	Citations
55	Can the HLA phenotype be used as a prognostic factor in breast carcinomas?. International Journal of Cancer, 1991, 47, 146-154.	2.3	50
56	Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. Cancer Immunology, Immunotherapy, 2007, 56, 88-94.	2.0	50
57	Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study. Cytotherapy, 2017, 19, 927-936.	0.3	49
58	HLA class I expression and HPVâ€16 sequences in premalignant and malignant lesions of the cervix. Tissue Antigens, 1993, 41, 65-71.	1.0	46
59	Methylated CpG points identified withinMAGE-1 promoter are involved in gene repression. , 1996, 68, 464-470.		46
60	Characterization of a gastric tumor cell line defective in MHC class I inducibility by both Î±â€and Î³â€interferon. Tissue Antigens, 1996, 47, 391-398.	1.0	45
61	Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunology, Immunotherapy, 2001, 49, 621-628.	2.0	45
62	Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: Implications for tumor evasion of T and NK cells. Human Immunology, 2009, 70, 854-857.	1.2	45
63	Negative Clinical Evolution in COVID-19 Patients Is Frequently Accompanied With an Increased Proportion of Undifferentiated Th Cells and a Strong Underrepresentation of the Th1 Subset. Frontiers in Immunology, 2020, 11, 596553.	2.2	45
64	Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). British Journal of Pharmacology, 2007, 150, 808-815.	2.7	44
65	Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunology, Immunotherapy, 2008, 57, 719-729.	2.0	43
66	HETEROGENEITY OF THE EXPRESSION OF CLASS I AND II HLA ANTIGENS IN HUMAN BREAST CARCINOMA. International Journal of Immunogenetics, 1986, 13, 247-254.	1.2	41
67	Association between C13ORF31, NOD2, RIPK2 and TLR10 polymorphisms and urothelial bladder cancer. Human Immunology, 2012, 73, 668-672.	1.2	40
68	DIFFERENTIAL EXPRESSION OF HLA CLASS I AND II ANTIGENS IN PRIMARY AND METASTATIC MELANOMAS. International Journal of Immunogenetics, 1986, 13, 219-228.	1.2	39
69	Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drugâ€induced liver injury. Liver International, 2013, 33, 1378-1385.	1.9	38
70	MHC expression on human tumors--its relevance for local tumor growth and metastasis. Seminars in Cancer Biology, 1991, 2, 3-10.	4.3	38
71	Novel genes and sex differences in COVID-19 severity. Human Molecular Genetics, 2022, 31, 3789-3806.	1.4	38
72	Tracking genetically engineered bacteria: monoclonal antibodies against surface determinants of the soil bacterium Pseudomonas putida 2440. Journal of Bacteriology, 1992, 174, 2978-2985.	1.0	37

#	Article	IF	Citations
73	Differential effect on U937 cell differentiation by targeting transcriptional factors implicated in tissue- or stage-specific induced integrin expression. Experimental Hematology, 1999, 27, 353-364.	0.2	37
74	Efficient Recovery of HLA Class I Expression in Human Tumor Cells After Beta2â€Microglobulin Gene Transfer Using Adenoviral Vector: Implications for Cancer Immunotherapy. Scandinavian Journal of Immunology, 2009, 70, 125-135.	1.3	36
75	VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population. Human Immunology, 2013, 74, 98-103.	1.2	36
76	HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15. Immunogenetics, 2018, 70, 647-659.	1.2	36
77	Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma. Tissue Antigens, 2006, 68, 303-310.	1.0	35
78	Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance. Cancer Immunology, Immunotherapy, 2016, 65, 47-59.	2.0	35
79	Phenotypic expression of histocompatibility antigens in human primary tumours and metastases. Clinical and Experimental Metastasis, 1989, 7, 213-226.	1.7	34
80	High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity. Cancer Immunology, Immunotherapy, 2005, 54, 141-148.	2.0	33
81	Analysis of HLAâ€“ABC locus-specific transcription in normal tissues. Immunogenetics, 2010, 62, 711-719.	1.2	33
82	Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression. Cancer Immunology, Immunotherapy, 2019, 68, 2015-2027.	2.0	33
83	Secretion by Trypanosoma cruzi of a peptidyl-prolyl cis-trans isomerase involved in cell infection. EMBO Journal, 1995, 14, 2483-90.	3.5	33
84	Adenovirus expressing Î²2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition. Cancer Gene Therapy, 2014, 21, 317-332.	2.2	32
85	Integration of high-risk human papillomavirus DNA is linked to the down-regulation of class I human leukocyte antigens by steroid hormones in cervical tumor cells. Cancer Research, 1997, 57, 937-42.	0.4	32
86	Differential Effects of IL-1Î² and Ibuprofen after Endotoxic Challenge in Mice. Journal of Surgical Research, 1997, 67, 199-204.	0.8	31
87	In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele. , 1998, 75, 317-323.		31
88	Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. Seminars in Cancer Biology, 2002, 12, 15-24.	4.3	31
89	Analysis of KIR gene frequencies in HLA class I characterised bladder, colorectal and laryngeal tumours. Tissue Antigens, 2007, 69, 220-226.	1.0	31
90	Protein kinase C-mediated regulation of the expression of CD14 and CD11 /CD18 in U937 cells. International Journal of Cancer, 1990, 45, 294-298.	2.3	30

#	Article	IF	Citations
91	Relationship of 4F2 antigen with local growth and metastatic potential of squamous cell carcinoma of the larynx. Cancer, 1990, 66, 1493-1498.	2.0	30
92	DIFFERENT PATTERNS OF HLA-DR ANTIGEN EXPRESSION IN NORMAL EPITHELIUM, HYPERPLASTIC AND NEOPLASTIC MALIGNANT LESIONS OF THE BREAST. International Journal of Immunogenetics, 1995, 22, 299-310.	1.2	30
93	A mutation determining the loss of HLA-A2 antigen expression in a cervical carcinoma reveals novel splicing of human MHC class I classical transcripts in both tumoral and normal cells. Immunogenetics, 2000, 51, 1047-1052.	1.2	30
94	Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy. Tissue Antigens, 2001, 57, 508-519.	1.0	30
95	Class I and II HLA antigen distribution in normal mucosa, adenoma and colon carcinoma: relation with malignancy and invasiveness. Experimental and Clinical Immunogenetics, 1987, 4, 144-52.	1.4	30
96	A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line. Immunogenetics, 2001, 53, 606-610.	1.2	29
97	Patterns of constitutive and IFN-Î³ inducible expression of HLA class II molecules in human melanoma cell lines. Immunogenetics, 2007, 59, 123-133.	1.2	29
98	Genome-wide differential genetic profiling characterizes colorectal cancers with genetic instability and specific routes to HLA class I loss and immune escape. Cancer Immunology, Immunotherapy, 2012, 61, 803-816.	2.0	29
99	Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of renal cell carcinoma patients. Human Immunology, 2010, 71, 309-313.	1.2	27
100	Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer. Oncotarget, 2016, 7, 71608-71619.	0.8	27
101	Distribution of the CD45R antigen in the maturation of lymphoid and myeloid series: the CD45R negative phenotype is a constant finding in T CD4 positive lymphoproliferative disorders. British Journal of Haematology, 1988, 69, 173-179.	1.2	26
102	Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation. Cancer Research, 1991, 51, 2463-8.	0.4	26
103	Molecular analysis of MHC-class-I alterations in human tumor cell lines. International Journal of Cancer, 1991, 47, 123-130.	2.3	25
104	HLA molecules in basal cell carcinoma of the skin. Immunobiology, 1992, 185, 440-452.	0.8	25
105	The Role of Toll-Like Receptor Polymorphisms in Acute Pancreatitis Occurrence and Severity. Pancreas, 2015, 44, 429-433.	0.5	25
106	TH1 and TH2 Cytokine Profiles as Predictors of Severity in Acute Pancreatitis. Pancreas, 2018, 47, 400-405.	0.5	25
107	MHC CLASS I AND II ANTIGENS ON GASTRIC CARCINOMAS AND AUTOLOGOUS MUCOSA. International Journal of Immunogenetics, 1989, 16, 413-423.	1.2	24
108	MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up. British Journal of Cancer, 1996, 74, 1801-1804.	2.9	24

#	Article	IF	Citations
109	Differential expression of MHC class II genes in lung tumour cell lines. International Journal of Immunogenetics, 1998, 25, 385-391.	1.2	21
110	Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression. Cancer Immunology, Immunotherapy, 2000, 48, 684-690.	2.0	21
111	Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue. Tissue Antigens, 2010, 75, 110-118.	1.0	21
112	Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis. Pharmacogenetics and Genomics, 2016, 26, 414-422.	0.7	21
113	Study of six X-linked tetranucleotide microsatellites: population data from five Spanish regions. International Journal of Legal Medicine, 2006, 120, 147-150.	1.2	20
114	Characterization of Monoclonal Antibodies Directed Against HLA Class II Molecules. Hybridoma, 1986, 5, 191-197.	0.9	19
115	Upmodulation by estrogen of HLA class I expression in breast tumor cell lines. Immunogenetics, 1994, 39, 161-7.	1.2	19
116	Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity. Cancer Immunology, Immunotherapy, 2011, 60, 869-882.	2.0	19
117	Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort. PLoS ONE, 2014, 9, e94675.	1.1	19
118	HLA Class I and II Expression in Rhabdomyosarcomas. Immunobiology, 1991, 182, 440-448.	0.8	18
119	Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients. Oncotarget, 2018, 9, 36929-36944.	0.8	18
120	K-ras mutations (codon 12) are not involved in down-regulation of mhc class-i genes in colon carcinomas. International Journal of Cancer, 1990, 46, 426-431.	2.3	17
121	Loss of HLA Heavy Chain and beta2-Microglobulin in HLA Negative Tumours. Scandinavian Journal of Immunology, 1991, 34, 147-152.	1.3	17
122	MHC Class I and II Gene Expression on Human Tumors. Advances in Experimental Medicine and Biology, 1988, 233, 119-128.	0.8	16
123	Study of HLA-A, -B, -C, -DRB1 and -DQB1 polymorphisms in COVID-19 patients. Journal of Microbiology, Immunology and Infection, 2022, 55, 421-427.	1.5	15
124	Lymphocyte Profile and Immune Checkpoint Expression in Drugâ€Induced Liver Injury: An Immunophenotyping Study. Clinical Pharmacology and Therapeutics, 2021, 110, 1604-1612.	2.3	15
125	Late pulmonary metastases of renal cell carcinoma immediately after post-transplantation immunosuppressive treatment: a case report. Journal of Medical Case Reports, 2008, 2, 111.	0.4	14
126	A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma. Human Immunology, 2009, 70, 60-64.	1.2	14

#	Article	IF	Citations
127	Looking for HLA-G expression in human tumours. Journal of Reproductive Immunology, 1999, 43, 263-273.	0.8	13
128	? 2 -microglobulin gene mutation is not a common mechanism of HLA class I total loss in human tumors. International Journal of Clinical and Laboratory Research, 2000, 30, 87-92.	1.0	13
129	Comparison of the SYBR Green and the hybridization probe format for real-time PCR detection of HHV-6. Microbiological Research, 2006, 161, 158-163.	2.5	13
130	Clinical Significance of Langerhans Cells in Squamous Cell Carcinoma of the Larynx. Journal of Oncology, 2012, 2012, 1-5.	0.6	13
131	Studies on CD11a and CD18 Molecules with Two New Monoclonal Antibodies: Differential Myelomonocytic Antigen Expression of PMA Treated HL60 and U937 Cell Lines. Hybridoma, 1989, 8, 13-23.	0.9	12
132	Characterization of CD44 Antigen during Lymphoid Ontogeny. Immunobiology, 1991, 183, 1-11.	0.8	12
133	Copy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of HLA Class I Alterations in Cancer. Cancers, 2021, 13, 5046.	1.7	12
134	Class II HLA Antigen Expression in Familial Polyposis Coli is Related to the Degree of Dysplasia. Immunobiology, 1990, 180, 138-148.	0.8	11
135	A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer. Annals of Surgical Oncology, 2019, 26, 2631-2639.	0.7	11
136	Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes. International Journal of Molecular Sciences, 2021, 22, 7248.	1.8	11
137	Promyelocytic leukemia (PML) nuclear bodies are disorganized in colorectal tumors with total loss of major histocompatibility complex class I expression and LMP7 downregulation. Tissue Antigens, 2004, 63, 446-452.	1.0	10
138	Different mechanisms can lead to the same altered HLA class I phenotype in tumors. Tissue Antigens, 2007, 69, 259-263.	1.0	10
139	A Monoclonal Antibody GR2110 Reactive With a P24 Antigen Present in a Subgroup of Acute Lymphoid Leukemias. Hybridoma, 1985, 4, 369-378.	0.9	9
140	Multiple mechanisms are responsible for the alteration in the expression of HLA class I antigens in melanoma. International Journal of Cancer, 2003, 105, 432-433.	2.3	9
141	HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine. Vaccines, 2022, 10, 402.	2.1	9
142	Production of Monoclonal Antibodies to Metacyclic Trypomastigotes ofTrypanosoma cruzi. Hybridoma, 1986, 5, 147-154.	0.9	7
143	Î²2-microglobulin gene mutation is not a common mechanism of HLA class I total loss in human tumors. International Journal of Clinical and Laboratory Research, 2000, 30, 87-92.	1.0	7
144	LncRNA-mRNA Co-Expression Analysis Identifies AL133346.1/CCN2 as Biomarkers in Pediatric B-Cell Acute Lymphoblastic Leukemia. Cancers, 2020, 12, 3803.	1.7	7

#	Article	IF	Citations
145	Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer. Pharmaceutics, 2022, 14, 505.	2.0	7
146	Molecular and flow cytometry characterization during the followâ€up of three simultaneous lymphoproliferative disorders: Hairy cell leukemia, monoclonal Bâ€cell lymphocytosis, and CD4⁺⁺/CD8^{+/â^'dim} Tâ€large granular lymphocytosisâ€"A case report. Cytometry Part B - Clinical Cytometry, 2011, 80B, 195-200.	0.7	6
147	A Monoclonal Antibody, GR7A4, Reacting with the T10 Antigen. Hybridoma, 1987, 6, 275-284.	0.9	5
148	Differential MAGE-1 Gene Expression in Two Variants of an Erythroleukemic Cell Line (K562). Immunobiology, 1995, 194, 449-456.	0.8	5
149	Interleukin-1Î² and Ibuprofen Effects on CD4/CD8 Cells after Endotoxic Challenge. Journal of Surgical Research, 1996, 65, 82-86.	0.8	5
150	Diffuse large Bâ€cell lymphoma in a renal allograft associated with Epsteinâ€Barr virus in the recipient: a case report and a review of lymphomas presenting in a transplanted kidney. Clinical Transplantation, 2008, 22, 512-519.	0.8	5
151	1137 THE HLA CLASS I B*1801 ALLELE INFLUENCES HEPATOCELLULAR EXPRESSION OF AMOXICILLIN-CLAVULANATE LIVER DAMAGE AND OUTCOME IN SPANISH PATIENTS. Journal of Hepatology, 2010, 52, S439.	1.8	5
152	Natural killer cell receptor expression reflects the role of human cytomegalovirus in the pathogenesis of a subset of CD4+ T-cell large granular lymphocytosis. Human Immunology, 2011, 72, 226-228.	1.2	5
153	Co-mutated CALR and MPL driver genes in a patient with myeloproliferative neoplasm. Annals of Hematology, 2017, 96, 1399-1401.	0.8	5
154	Association between Genetic Polymorphisms of Inflammatory Response Genes and Acute Pancreatitis. Immunological Investigations, 2019, 48, 585-596.	1.0	5
155	Different CD45 and CD45R Epitopes Involved in T Cell Proliferation and NK Cytotoxicity. Hybridoma, 1989, 8, 1-11.	0.9	4
156	Dexamethasone induces altered binding of regulatory factors to HLA class I enhancer sequence in MCF-7 breast tumour cell line. Cancer Immunology, Immunotherapy, 1998, 46, 194-200.	2.0	4
157	Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. Biomedicines, 2022, 10, 55.	1.4	4
158	Analysis of six tetranucleotide polymorphisms of the X-chromosome in different Spanish regions. International Congress Series, 2006, 1288, 304-306.	0.2	3
159	HLA Class I Expression, Tumor Escape and Cancer Progression. Current Cancer Therapy Reviews, 2008, 4, 105-110.	0.2	3
160	Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanateâ€"Induced Liver Injury in Spanish Patients. Frontiers in Pharmacology, 2016, 7, 280.	1.6	3
161	Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. International Journal of Cancer, 1999, 83, 91-97.	2.3	3
162	A study of GRM1 monoclonal antibody that reacts with natural killer cells and granulocytes. Natural Immunity and Cell Growth Regulation, 1987, 6, 99-108.	0.2	3

#	Article	IF	Citations
163	Phenotypic Analysis and Growth Response to Different Growth Hormone Treatment Schedules in Two Siblings with an Inactivating Mutation in the Growth Hormone-Releasing Hormone Receptor Gene. Journal of Pediatric Endocrinology and Metabolism, 2004, 17, 793-800.	0.4	2
164	Acute myeloid leukaemia of donor cell origin developing 17 years after allogenic hematopoietic cell transplantation for acute promyelocytic leukaemia. International Journal of Biomedical Science, 2012, 8, 244-8.	0.5	2
165	Study of the monoclonal antibodies against blood group B and A + B (group 2) of the First international workshop. Pattern of reaction with colon carcinomas. Revue FranÃ§aise De Transfusion Et Immuno-hÃ©matologie, 1987, 30, 609-611.	0.1	1
166	Study of the monoclonal antibodies against blood group A (group N. 1) of the First international workshop. Pattern of reaction with normal colon mucosa and colon carcinomas. Revue FranÃ§aise De Transfusion Et Immuno-hÃ©matologie, 1987, 30, 485-488.	0.1	1
167	Corrigendum to â€œAnalysis of IL-10, IL-4 and TNF-Î± polymorphisms in drug-induced liver injury (DILI) and its outcomeâ€•[J Hepatol 49 (2008) 107â€“114]. Journal of Hepatology, 2009, 50, 636.	1.8	1
168	In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele. , 1998, 75, 317.		1
169	Founding mutations explains hotspots of polycystic kidney disease in Southern Spain. CKJ: Clinical Kidney Journal, 2021, 14, 1845-1847.	1.4	1
170	Downmodulation of HLA class I expression by dexamethasone in MCF-7 cell line. Revista EspaÃ±ola De FisiologÃa, 1997, 53, 355-60.	0.0	1
171	Expansion of cells with trisomy 12 associated with progressive lymphocytosis and a dramatic change in chimera status in a patient with chronic lymphocytic leukemia. Haematologica, 2002, 87, ECR25.	1.7	1
172	Major Histocompatibility Complex Class I Chain-Related Î± (MICA) STR Polymorphisms in COVID-19 Patients. International Journal of Molecular Sciences, 2022, 23, 6979.	1.8	1
173	Re-expression of HLA class I antigens and restoration of antigen-specific cytotoxic T lymphocytes in melanoma cells following 5-AZA-2â€²deoxycytidine treatment. European Journal of Cancer, 2001, 37, S417-S418.	1.3	0
174	Evaluation of functional single nucleotide polymorphisms of different genes coding for the immunoregulatory molecules in patients with monoclonal large granular lymphocyte lymphocytosis. Human Immunology, 2008, 69, 101-107.	1.2	0
175	312 GENOTYPE DISTRIBUTION OF THE HEPATIC CANALICULAR TRANSPORTER ABCC2 â€“ 24C>T POLYMORPHISM IS NOT RELATED TO DRUG-INDUCED IDIOSYNCRATIC LIVER INJURY (DILI). RELEVANCE OF ETHNIC VARIANTS IN EUROPEANS. Journal of Hepatology, 2009, 50, S122.	1.8	0
176	684 EFFECTS OF CHEMICAL MOIETIES AND POLYMORPHISMS IN THE HUMAN ABC TRANSPORTER ABCB1 (P-GLYCOPROTEIN/MDR1) IN DRUG-INDUCED LIVER INJURY. Journal of Hepatology, 2011, 54, S275.	1.8	0
177	1378 EFFECT OF ABCC2 HAPLOTYPES ON INDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) SUSCEPTIBILITY. Journal of Hepatology, 2012, 56, S541.	1.8	0
178	Autoantibody presentation in Drug-Induced Liver Injury (DILI) and idiopathic Autoimmune Hepatitis (AIH): The influence of HLA alleles. Clinical Therapeutics, 2015, 37, e119-e120.	1.1	0
179	Comparison of cytokine profiles in idiosyncratic drug-induced liver injury, acute non-drug-induced hepatitis and controls. Journal of Hepatology, 2017, 66, S80-S81.	1.8	0
180	A combination of positive tumor HLA-I and negative PD-L1 expression provides an immune rejection mechanism in bladder cancer. European Urology Open Science, 2020, 19, e1428.	0.2	0

#	Article	IF	Citations
181	MHC Class I Antigens and the Tumor Microenvironment. , 2013, , 253-286.		0
182	Comparative analysis of lymphoid subsets in peripheral blood and tumor-infiltrating lymphocytes of lung cancer patients. , 2015, , .		0
183	CRC: A Darwinian model of cellular immunoselection. , 2022, , 529-541.		0
184	The monoclonal antibody GRC1 produced against human cornea recognizes a common determinant of collagen. Investigative Ophthalmology and Visual Science, 1990, 31, 290-3.	3.3	0
185	Microsatellite instability in cervical intraepithelial neoplasia. Journal of Experimental and Clinical Cancer Research, 1998, 17, 361-6.	0.4	0